These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 33084382)

  • 1. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
    Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
    AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
    [No Abstract]   [Full Text] [Related]  

  • 2. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
    Wang ZJ; Behr S; Consunji MV; Yeh BM; Ohliger MA; Gao K; Ko AH; Cinar P; Tempero MA; Collisson EA
    AJR Am J Roentgenol; 2018 Nov; 211(5):1010-1019. PubMed ID: 30063366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
    J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience.
    Hamdy A; Ichikawa Y; Toyomasu Y; Nagata M; Nagasawa N; Nomoto Y; Sami H; Sakuma H
    Radiology; 2019 Sep; 292(3):628-635. PubMed ID: 31287389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
    Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of
    Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
    Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT,
    Yoo J; Lee JM; Joo I; Lee DH; Yoon JH; Yu MH; Jang JY; Lee SH
    Cancer Imaging; 2023 May; 23(1):49. PubMed ID: 37217958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
    Sakane M; Tatsumi M; Hori M; Onishi H; Tsuboyama T; Nakamoto A; Ota T; Eguchi H; Wakasa K; Hatazawa J; Tomiyama N
    Eur J Radiol; 2017 Sep; 94():64-69. PubMed ID: 28712692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and
    Jeong B; Oh M; Lee SS; Kim N; Kim JS; Lee W; Kim SC; Kim HJ; Kim JH; Byun JH
    Korean J Radiol; 2024 Jul; 25(7):644-655. PubMed ID: 38942458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival.
    Lee W; Oh M; Kim JS; Park Y; Kwon JW; Jun E; Song KB; Lee JH; Hwang DW; Yoo C; Kim KP; Jeong JH; Chang HM; Ryoo BY; Park SY; Kim SC
    Br J Surg; 2021 Dec; 109(1):61-70. PubMed ID: 34378010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of residual tumor and overall survival after first-line surgery in patients with pancreatic ductal adenocarcinoma using preoperative magnetic resonance imaging findings.
    Bae JS; Kim JH; Kang HJ; Han JK
    Acta Radiol; 2022 Apr; 63(4):435-446. PubMed ID: 33682455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade.
    Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A
    J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
    Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperpolarized
    Gordon JW; Chen HY; Nickles T; Lee PM; Bok R; Ohliger MA; Okamoto K; Ko AH; Larson PEZ; Wang ZJ
    J Magn Reson Imaging; 2024 Aug; 60(2):741-749. PubMed ID: 38041836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?
    Denecke T; Rau B; Hoffmann KT; Hildebrandt B; Ruf J; Gutberlet M; Hünerbein M; Felix R; Wust P; Amthauer H
    Eur Radiol; 2005 Aug; 15(8):1658-66. PubMed ID: 15806369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline Characteristics and Use of Pretherapeutic 18 F-Fluorodeoxyglucose-PET for Pancreatic Cancer.
    Carlson DM; Abdelrahman AM; Adjei Antwi SK; Tomlinson JL; Trivedi K; Karbhari A; Patnam Gopal Chetty N; Halfdanarson TR; Goenka AH; Truty MJ
    J Am Coll Surg; 2024 Jul; 239(1):9-17. PubMed ID: 38445645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Duch J; Fuster D; Muñoz M; Fernández PL; Paredes P; Fontanillas M; Skaltsa K; Domènech B; Lomeña F; Pons F
    Q J Nucl Med Mol Imaging; 2012 Jun; 56(3):291-8. PubMed ID: 22695339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
    AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
    [No Abstract]   [Full Text] [Related]  

  • 20. Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.
    Dunet V; Halkic N; Sempoux C; Demartines N; Montemurro M; Prior JO; Schmidt S
    Eur Radiol; 2021 Feb; 31(2):992-1001. PubMed ID: 32851447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.